Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7161662 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2LMNAALDH1A1HPGDKDM4E | |
| SCHEMBL5838994 | 0.86 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNAALDH1A1HPGDKDM4E | |
| Bicarbonate SCHEMBL5718008 | 0.84 | SMN1; SMN2 (0.61) | SMN1; SMN2LMNAALDH1A1HPGDKDM4E | |
| SCHEMBL5717993 | 0.83 | KCNQ3 (0.46) | SMN1; SMN2LMNAALDH1A1HPGDKDM4E | |
| SCHEMBL7067895 | 0.82 | KCNQ3 (0.45) | SMN1; SMN2LMNAALDH1A1HPGDKDM4E | |
| SCHEMBL7776521 | 0.79 | POLB (0.71) | SMN1; SMN2LMNAALDH1A1HPGDKDM4E | |
| SCHEMBL5838998 | 0.75 | SMN1; SMN2 (0.48) | SMN1; SMN2LMNAALDH1A1HPGDKDM4E | |
| SCHEMBL6737598 | 0.75 | SLC6A2 (0.45) | MEN1KMT2A | |
| SCHEMBL6733188 | 0.72 | ALDH1A1 (0.40) | SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL6844383 | 0.71 | KCNQ3 (0.49) | SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1318977-B1 | SUBSTITUTED PHENYLCYCLOHEXANE CARBOXYLIC ACID AMIDES AND THE USE THEREOF | BAYER HEALTHCARE AG (DE) | 2006-12-06 | — | — | EP | disclosed |
| US-7074780-B2 | Substituted phenylcyclohexanecarboxamides and their use | BAYER AKTIENGESELLSCHAFT (DE) | 2006-07-11 | — | — | US | disclosed |
| US-20040122004-A1 | Substituted phenylcyclohexanecarboxamides and their use | BAYER AKTIENGESELLSCHAFT (DE) | 2004-06-24 | — | — | US | disclosed |
| US-6649616-B2 | For therapy and prophylaxis of cardiovascular disorders caused by ischaemia | BAYER AKTIENGESELLSCHAFT (DE) | 2003-11-18 | — | — | US | disclosed |
| US-20030008881-A1 | Substituted phenylcyclohexanecarboxamides and their use | BAYER AKTIENGESELLSCHAFT (DE) | 2003-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008881-A1 | Substituted phenylcyclohexanecarboxamides and their use | TNNI3, PAH, P4HA1 | SMN1; SMN2 2130/4885LMNA 94/4885ALDH1A1 349/4885 |
| US-20040122004-A1 | Substituted phenylcyclohexanecarboxamides and their use | TNNI3, PAH, P4HA1 | SMN1; SMN2 2130/4885LMNA 94/4885ALDH1A1 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.